How Far Can This Blockbuster Take Johnson & Johnson (JNJ)?

Page 1 of 2

Johnson & Johnson (NYSE:JNJ) may offer well-known personal care products such as Listerine and Neutrogena, but it also boasts an impressive portfolio of market-leading therapeutic compounds. The health care leader was one of the few to show growth in both worldwide pharmaceutical sales and earnings last year, which grew to $25 billion and $3.86 per share respectively. It finds itself in an enviable position heading into 2013 as one of the best-positioned companies to tackle the patent cliff head on.

Even with the recent success, there is no time to rest on laurels in the highly competitive landscape of pharma and biotech. The industry’s most successful drugs are under constant pressure from generics, which are either already on the market or timing their entrance for the moment exclusivity is lost. Luckily, 2012 showed that several new drugs are already shaping up to be critical driving forces in the company’s future. Today, we will look at the anti-inflammatory biologic Remicade.

Johnson & Johnson (NYSE:JNJ)Immunology goes beast mode
Remicade (infliximab) is a monoclonal antibody that targets and suppresses tumor necrosis factor-alpha, or TNF-alpha, which regulates immune cells that induce fever and inflammation when fighting infection or disease. The biologic gained its first approval in 1998 and never looked back.

In fact, it was a major factor in shifting the standard of care in autoimmune disorders from the small molecule methotrexate to stand-alone therapeutic proteins or combinational therapies. It was also the first TNF inhibitor to be approved in three distinct therapies and is now approved for 16 indications. According to the company, Remicade has treated more than 1.5 million patients in the past 17 years.

As you can probably tell, Remicade is easily the leading drug for Johnson & Johnson. Not only does it generate 78% of all biologics revenue, but it also single-handedly topped the sales of the company’s total infectious disease and oncology segments in 2012.

Source: SEC filings. Dollar amounts in millions.

A recent battle over Remicade with Merck & Co., Inc. (NYSE:MRK), which generated just over $2 billion from the biologic last year, decided who had exclusive rights to key markets outside of the United States and how profits would be split elsewhere. Judging by last year’s results, it would seem that Johnson & Johnson got the better end of the deal.

Do you hear footsteps?
Other TNF-alpha inhibitors approved for various indications include Simponi (golimumab) from Johnson & Johnson and Merck; Humira (adalimumab) from AbbVie Inc (NYSE:ABBV); and Enbrel (entanercept) from Amgen, Inc. (NASDAQ:AMGN). Due to the scope of approvals granted to various therapeutic proteins, Remicade faces competition in some indications while enjoying exclusive use — such as orphan drug status for pediatric ulcerative colitis — in others.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

The 15 Most Famous Carl Icahn Quotes

10 Scary Animals that are Actually Harmless

The 8 Most Famous Singer-Actors in Entertainment

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!